No-Spa Forte Neo (Drotaverine Hydrochloride)

Drotaverine Hydrochloride is an antispasmodic that relaxes smooth muscle in the gastrointestinal, biliary, urinary and uterine systems.

• Abdominal and gastrointestinal cramping: reduces the intensity and frequency of painful muscle contractions in the gut.
• Biliary colic: alleviates pain caused by gallbladder muscle spasm during bile flow obstruction.
• Urinary tract spasm: relaxes bladder and ureter smooth muscle to ease discomfort and urgency.
• Dysmenorrhea: diminishes menstrual pain by relaxing uterine smooth muscle during the menstrual cycle.

• Drotaverine Hydrochloride inhibits phosphodiesterase enzymes, primarily PDE‑4, leading to increased intracellular cyclic AMP levels in smooth‑muscle cells. Elevated cAMP reduces calcium influx, causing relaxation of smooth muscle in the gastrointestinal, genitourinary and vascular tissues. This action diminishes spasm without significant anticholinergic effects, providing symptomatic relief in conditions characterized by involuntary muscle contraction.

Adverse reactions to Drotaverine Hydrochloride are generally mild but can include more serious events.

Common Side Effects

• Nausea
• Dizziness
• Headache
• Dry mouth
• Hypotension
• Blurred vision

Serious or Rare Side Effects

• Allergic reactions such as rash, itching or angioedema
• Severe hypotension leading to fainting
• Cardiac arrhythmias
• Hepatic enzyme elevation
• Blood dyscrasias (e.g., neutropenia, thrombocytopenia)

When prescribing Drotaverine Hydrochloride, clinicians should consider several precautionary measures to ensure safe use.

• Assess renal and hepatic function: adjust use in patients with significant impairment.
• Use cautiously in cardiovascular disease: monitor blood pressure and heart rate.
• Avoid in known hypersensitivity to drotaverine or excipients.
• Pregnancy and lactation: safety not established; prescribe only if benefits outweigh risks.
• Concomitant use with other smooth‑muscle relaxants: may increase antispasmodic effect.
• Store below 25°C: keep in the original pack, protect from moisture.

Drotaverine Hydrochloride may interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid)

• Co‑administration with other phosphodiesterase inhibitors: risk of excessive smooth‑muscle relaxation.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase drotaverine plasma levels.
• Anticholinergic agents: additive antispasmodic effect leading to severe constipation.

Moderate Interactions (Monitor Closely)

• Antihypertensive drugs: potential additive hypotensive effect.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs): may increase gastrointestinal irritation.
• Diuretics: monitor electrolyte balance, especially potassium.
• Antidepressants affecting serotonin: observe for rare serotonin syndrome signs.